Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on October 26, 2017, covering events occurring on October 25, 2017. The filing details the entry into a Material Definitive Agreement with Maxim Group LLC regarding a previously announced underwritten public offering.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a contractual amendment related to a capital raising event.
Material Changes and Agreements
On October 25, 2017, the Company amended its Underwriting Agreement dated September 29, 2017, with Maxim Group LLC via a Letter Agreement. Key provisions include:
- Offering Details: The agreement relates to the issuance and sale of 21,250,000 shares of voting common stock.
- 120-Day Tail Period: The Company is permitted to issue common stock or equivalents at or above $0.20 per share during the 120 days following the September 29 signing date.
- Financial Advisor Role: Maxim Group LLC is designated as the sole and exclusive financial advisor for any financing conducted during the 120-day tail period.
- Fee Structure: Maxim is entitled to a fee of 7.0% of total gross proceeds from investors contacted by them during the tail period. Additionally, the fee tail for financings with certain investors within 12 months of the offering was increased from 3.5% to 7.0%.
- Debt Modification: The Company may amend or extend debt obligations provided no shares are issued at a conversion price below $0.40 per share.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond the contractual limitations imposed by the Letter Agreement. The document notes that the description of the agreement is qualified by reference to the full text filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the full text of the Letter Agreement (Exhibit 10.1) for specific exceptions to the fee structure and issuance limitations.
- Confirm the status of the 21,250,000 share offering announced on September 29, 2017.
- Monitor future financing activities within the 120-day tail period to assess the impact of the 7.0% advisory fee.
- Review any subsequent debt amendments to ensure compliance with the $0.40 per share conversion price floor.